(-)-Coclaurine hydrochloride

CAS No. 3422-42-2

(-)-Coclaurine hydrochloride( (-)-Coclaurine hydrochloride (486-39-5 Free base) )

Catalog No. M29120 CAS No. 3422-42-2

(-)-Coclaurine hydrochloride is an antagonist of nAChRs isolated from Sarcopetalum harveyanum.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 249 In Stock
5MG 249 In Stock
10MG 369 In Stock
25MG 562 In Stock
50MG 770 In Stock
100MG 1032 In Stock
200MG 1376 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    (-)-Coclaurine hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    (-)-Coclaurine hydrochloride is an antagonist of nAChRs isolated from Sarcopetalum harveyanum.
  • Description
    (-)-Coclaurine hydrochloride is an antagonist of nAChRs isolated from Sarcopetalum harveyanum.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    (-)-Coclaurine hydrochloride (486-39-5 Free base)
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    AChR
  • Recptor
    AChR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    3422-42-2
  • Formula Weight
    321.8
  • Molecular Formula
    C17H20ClNO3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C([C@H]1C=2C(=CC(OC)=C(O)C2)CCN1)C3=CC=C(O)C=C3.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Euphorbia factor L1

    Euphorbia factor L1 inhibits the efflux of ABCB1 in KBv200 and MCF-7/adr cells, does not downregulate their expression either in mRNA or protein level.

  • GAT107

    GAT107 is a novel and potent α7 nicotinic cholinergic receptor modifier agonist and modulator with anti-inflammatory activity that reverses injury perception in a mouse model of neuropathic pain.

  • ±-Darifenacin

    (±)-Darifenacin ((±)-UK-88525) is a potential inhibitor of p53-MDM2 interaction with anticancer activity for the study of overactive bladder, Alzheimer's disease and Parkinson's disease.